Edwards Lifesciences (NYSE:EW) VP Sells 11,340 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $83.83, for a total value of $950,632.20. Following the sale, the vice president directly owned 50,356 shares of the company’s stock, valued at $4,221,343.48. This represents a 18.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $0.69 on Wednesday, hitting $83.97. The company had a trading volume of 2,897,414 shares, compared to its average volume of 4,457,593. The stock has a market cap of $48.73 billion, a price-to-earnings ratio of 36.19, a P/E/G ratio of 3.79 and a beta of 0.97. The stock has a 50 day moving average price of $81.19 and a 200 day moving average price of $78.88. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Econ Financial Services Corp acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $889,000. Randolph Co Inc acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth $301,000. OMERS ADMINISTRATION Corp lifted its position in shares of Edwards Lifesciences by 97.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after buying an additional 21,950 shares during the last quarter. Pacific Capital Partners Ltd bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $1,760,000. Finally, Arkadios Wealth Advisors acquired a new stake in Edwards Lifesciences in the second quarter valued at about $300,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on EW. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Truist Financial set a $92.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, December 5th. Mizuho lifted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, BTIG Research restated a “buy” rating and issued a $103.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.09.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.